Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Harrow, Inc. or Ligand Pharmaceuticals Incorporated because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Harrow, Inc. and Ligand Pharmaceuticals Incorporated compare based on key financial metrics to determine which better meets your investment needs.

About Harrow, Inc. and Ligand Pharmaceuticals Incorporated

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.

Latest Pharmaceuticals and Harrow, Inc., Ligand Pharmaceuticals Incorporated Stock News

As of June 12, 2026, Harrow, Inc. had a $1.4 billion market capitalization, compared to the Pharmaceuticals median of $603.3 million. Harrow, Inc.’s stock is down 23.2% in 2026, up 13.4% in the previous five trading days and up 19.08% in the past year.

Currently, Harrow, Inc. does not have a price-earnings ratio. Harrow, Inc.’s trailing 12-month revenue is $268.7 million with a -5.6% net profit margin. Year-over-year quarterly sales growth most recently was -7.5%. Analysts expect adjusted earnings to reach $0.443 per share for the current fiscal year. Harrow, Inc. does not currently pay a dividend.

As of June 12, 2026, Ligand Pharmaceuticals Incorporated had a $5.1 billion market cap, putting it in the 68th percentile of all stocks. Ligand Pharmaceuticals Incorporated’s stock is up 35.2% in 2026, up 7.8% in the previous five trading days and up 121.46% in the past year.

Currently, Ligand Pharmaceuticals Incorporated’s price-earnings ratio is 34.1. Ligand Pharmaceuticals Incorporated’s trailing 12-month revenue is $274.5 million with a 55.9% net profit margin. Year-over-year quarterly sales growth most recently was 14.1%. Analysts expect adjusted earnings to reach $9.101 per share for the current fiscal year. Ligand Pharmaceuticals Incorporated does not currently pay a dividend.

How We Compare Harrow, Inc. and Ligand Pharmaceuticals Incorporated Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Harrow, Inc. and Ligand Pharmaceuticals Incorporated’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Harrow, Inc. and Ligand Pharmaceuticals Incorporated Stock Value Grades

Company	Ticker	Value
Harrow, Inc.	HROW	F
Ligand Pharmaceuticals Incorporated	LGND	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Harrow, Inc. has a Value Score of 4, which is Ultra Expensive. Ligand Pharmaceuticals Incorporated has a Value Score of 13, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Harrow, Inc. or Ligand Pharmaceuticals Incorporated has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Harrow, Inc. or Ligand Pharmaceuticals Incorporated is the better investment when it comes to value.

Harrow, Inc. and Ligand Pharmaceuticals Incorporated Growth Grades

Company	Ticker	Growth
Harrow, Inc.	HROW	D
Ligand Pharmaceuticals Incorporated	LGND	B

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Harrow, Inc. has a Growth Score of 40, which is Weak. Ligand Pharmaceuticals Incorporated has a Growth Score of 64, which is Strong.

The Growth Grade Winner: Ligand Pharmaceuticals Incorporated

As you can clearly see from the Growth Grade breakdown above, Ligand Pharmaceuticals Incorporated has a more attractive growth grade than Harrow, Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, Ligand Pharmaceuticals Incorporated could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Harrow, Inc. and Ligand Pharmaceuticals Incorporated’s Momentum Grades

Company	Ticker	Momentum
Harrow, Inc.	HROW	C
Ligand Pharmaceuticals Incorporated	LGND	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Harrow, Inc. has a Momentum Score of 60, which is Average. Ligand Pharmaceuticals Incorporated has a Momentum Score of 87, which is Very Strong.

The Momentum Grade Winner: Ligand Pharmaceuticals Incorporated

As you can clearly see from the Momentum Grade breakdown above, Ligand Pharmaceuticals Incorporated is considered to have stronger momentum compared to Harrow, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Ligand Pharmaceuticals Incorporated could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Harrow, Inc. and Ligand Pharmaceuticals Incorporated Grades

In addition to Growth, Value and Momentum, A+ Investor also provides grades for Estimate Revisions and Quality.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Harrow, Inc. and Ligand Pharmaceuticals Incorporated pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Harrow, Inc. or Ligand Pharmaceuticals Incorporated Stock?

Overall, Harrow, Inc. stock has a Value Score of 4, Growth Score of 40 and Momentum Score of 60.

Ligand Pharmaceuticals Incorporated stock has a Value Score of 13, Growth Score of 64 and Momentum Score of 87.

Comparing Harrow, Inc. and Ligand Pharmaceuticals Incorporated’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.